Default company panoramic image

Vaccinogen, Inc.

Autologous cancer vaccine using patients' own tumor to prevent the recurrence of colon cancer & other carcinomas. $5b revenue potential.

  • Stage Full Product Ready
  • Industry Biotechnology
  • Location Frederick, MD, USA
  • Currency USD
  • Founded October 2007
  • Employees 16
  • Website

Company Summary

Prevents recurrence of cancer by using the patient's own tumor to make a patient-specific vaccine. The first customers are those with stage II colon cancer followed by stage III, renal, melanoma, ovarial and possibly lung cancer. All solid tumors are potentially treated using our patented vaccine approach. In the last phase 3 trial, recurrence dropped from 1 out of 3 patients to 1 out of 10 patients. We make colon cancer a manageable disease.


  • Default avatar
    Debra R. Hoopes
    Chief Financial Advisor

    Is responsible for all financial aspects of the Company including 15c211 filing preparations, external audit preparations and S1 filing preparation. 20+ years of corporate finance, accounting & management experience in various industries. Includes both private and public companies in CFO role with hands-on executive management & proven track record in cost cutting, reorganization, acquisitions, business plan implementation & change management.

  • Default avatar
    Michael G. Hanna
    Chairman and Chief Executive Officer & Co- Founder

    Discoverer & developer of OncoVAX & pioneer in cancer vaccines. Obtained FDA approval for TICE BCG which treats bladder cancer. Former director of the National Cancer Institutes, Frederick Cancer Research Center, managing over 2,000 scientists and technicians. Authored 225 publications. Ph.D. in experimental pathology & immunology from the University of Tennessee. Chief Operating Officer of Organon Teknika. President & CEO of PerImmune.

  • Default avatar
    Andrew Lewis Tussing
    President, Chief Operating Officer & Co-Founder

    Been founding and building businesses throughout career. Co-founded Vaccinogen in 2007 and has raised $50 million to fund its pivotal trial launch. Held leading role in building operations.

    Recently active in investment banking activities & strategic advisor to companies to positioning for growth. Director at Pershing (Bank of NY & Credit Suisse), Deutsche Bank.

    VP at Alex. Brown & Sons & grew its correspondent services business effort.

  • Default avatar
    Dinand Van der Linde
    Managing Director & Business Development

    Develops & implements OncoVAX marketing strategy. Previously with Bristol Myers Squibb

    Introduced chemotherapy drugs in Europe. MD of The Geon Foundation for Regional & Economic Research.

    MSC & M.A. from the Free University of Amsterdam.

  • Default avatar
    John Powers
    Logistics and Manufacturing Head

    Built & sold 3 biotech companies. Owns KsD Scientific, a biotechnology-consulting firm. Initiated Baltimore BioWorks a vocational biotech training co. Involved in Phase III clinical trial work with Roche. Worked with the CDC & the NIH. Author of numerous papers, abstracts and manuals, holds four biotech product patents and has filed and received over a dozen FDA 510(k) approvals.

    Ph.D., MBA and BS at the University of Maryland

  • Default avatar
    Sanda Milder
    Site Director - Head of Manufacturing

    Responsible for overall plant. Oversees & coordinates vaccine manufacturing process &r all administrative functions. Maintains all SOP's & ensures safe, clean manufacturing environment & product.

    BS in Biochemistry, Cum Laude; & certifications in QC & QA


  • Default avatar
    Venable, LLP
    Default avatar
    BDO, Ryan Sharkey & Biegel & Waller

Previous Investors

  • Default avatar
    Various institutional high net worth and family offices
    Default avatar
    MPM Capital